European Companies Search Engine
EU funding (€2,728,340): Prevention of SARS-CoV-2 infection through development and clinical testing of a novel Virus Like Particle (VLP) vaccine Hor1 Apr 2020 EU Research and Innovation programme "Horizon"
Text
Prevention of SARS-CoV-2 infection through development and clinical testing of a novel Virus Like Particle (VLP) vaccine
Our aim is to perform pre-clinical and clinical evaluation of a potential Wuhan Coronavirus vaccine candidate. The vaccine will be based on Virus-Like Particle (VLP) display of the SARS-CoV-2 Spike protein antigen. AdaptVac's VLP display technology has been shown to significantly improve vaccine immunogenicity, longevity and efficacy, for a wide range of viral and parasite diseases in pre-clinical studies (including flu and malaria). A unique feature of the technology is its two-component approach. The VLP is generic to all vaccines, and produced at >1g/L yields using E. coli. The disease antigen is produced in any expression system, allowing the most challenging antigens to be successfully produced. The VLP and antigen is then simply mixed, and a spontaneous, irreversible, conjugation occurs under physiological conditions. This results in site-specific, directional, and high-density display of the antigen on the VLP surface. The antigen will be produced using ExpreS2ion's Drosophila S2 insect cells based on the trimetric spike antigen. Furthermore, E. coli and baculovirus will be tested for Spike protein variants. The vaccine candidates will be tested pre-clinically using in vitro viral neutralization assays and possibly animal challenge models as they become available at LUMC. ExpreS2ion will develop the production processes and transfer these for GMP manufacture of the VLP and vaccine antigen, outsourced, to AGC Biologics. Finally, a phase I/IIa study will be performed at Radboud University Medical Center in the Netherlands. A surrogate marker of protection will be established by showing protection in animal models using passive transfer of participant sera, or by in vitro SARS-CoV-2 viral neutralization. This project is focused on delivering a scalable vaccine, ready for testing in the field, which has been shown to be safe in humans and effective in in vitro or animal models.
Funded Companies:
| Company name | Funding amount |
| ACADEMISCH ZIEKENHUIS LEIDEN | €50,625 |
| Adaptvac ApS | €1,481,250 |
| EBERHARD KARLS UNIVERSITAET TUEBINGEN | €295,898 |
| Expres2ION Biotechnologies ApS | €160,883 |
| Kobenhavns Universitet | €128,648 |
| STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM | €544,890 |
| STICHTING RADBOUD UNIVERSITEIT | €0.00 |
| Universitaetsklinikum Tuebingen | €0.00 |
| WAGENINGEN UNIVERSITY | €66,148 |
Source: https://cordis.europa.eu/project/id/101003608
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "ACADEMISCH ZIEKENHUIS LEIDEN - EU funding (€2,728,340): Prevention of SARS-CoV-2 infection through development and clinical testing of a novel Virus Like Particle (VLP) vaccine"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
